The current standards of care involve using anti-VEGF agents, which selectively target extracellular VEGF. We've been doing this for years and those drugs do a good job, but there are limitations ...

There has been dramatic growth in the number of intravitreal injections performed annually. This paper features expert panel consensus regarding the use of intravitreal injections and serves as an ...

To assess the long-term safety and efficacy of intravitreal triamcinolone acetonide injection in the management of macular oedema caused by central, hemi-, and branch retinal vein occlusion (CRVO, ...

Please provide your email address to receive an email when new articles are posted on . There are more options available than just the standard methods. Choices need to be made for every step of the ...

In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. BARCELONA, Spain — A subgroup analysis of the DAVIO 2 ...

STOCKHOLM — Simple changes, like minimizing patient visits and reducing the use of nonsterile gloves, can make a big difference in the environmental impact of intravitreal injections without ...

A dexamethasone implant significantly outperformed ranibizumab (Lucentis) and methotrexate for intravitreal treatment of persistent/recurrent uveitic macular edema, according to results of a ...

Learn everything you need to know about Dexamethasone Intravitreal Implant-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects ...

1.1 Dexamethasone intravitreal implant is recommended as an option for treating visual impairment caused by diabetic macular oedema in adults only if their condition has not responded well enough to, ...

Due to an aging population, visual impairment from neovascular age-related macular degeneration (nAMD) is increasing in the United States. Despite unprecedented improvements in vision preservation ...